Mereo BioPharma Group Q2 2026 Earnings Report

Mereo BioPharma Group EPS Results

• Actual EPS: -$0.01
• Consensus EPS: -$0.01
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Mereo BioPharma Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mereo BioPharma Group Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 11, 2026
• Conference Call Time: 8:00AM ET

Mereo BioPharma Group (NASDAQ:MREO) plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives.

Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.